No single ticker was named. Healthcare ETFs are one way for retail investors to get exposure. Not a recommendation.
US pharma faces severe structural funding headwinds
The bear case for US pharmaceutical innovation centers on regulatory inconsistency and the profit-limiting impact of Most Favored Nation pricing.
The argument
The guest argued that US pharmaceutical returns are already below the cost of capital, and policies like Most Favored Nation (MFN) pricing will further damage profitability. Additionally, regulatory unpredictability—such as CBER changing approval stances post-trial—disincentivizes R&D investment.
The thesis, stress-tested
✓ What validates it
- ✓Implementation of MFN pricing policies in the US
- ✓Further public reports of CBER rejecting trial results after approving designs
▸ Risks discussed
- ▸Deregulation efforts under the Trump administration could offset some headwinds
- ▸Increased adoption of automated AI bio-researchers could lower R&D costs